【摘要】 目的:探讨文拉法辛联合米氮平治疗难治性抑郁症患者的疗效。方法:31例难治性抑郁症患者给予文拉法辛联合米氮平治疗,疗程8周。于治疗前及治疗1、2、4、6和8周应用汉密尔顿抑郁量表(HAMD)和治疗中出现的症状量表(TESS)分别评定疗效和不良反应。结果:治疗2周,HAMD评分从治疗前(23.32±5.25)分降至(19.03±4.27)分(t=3.53,P<0.01);治疗8周,HAMD评分降至(8.77±5.18)分(t=9.83,P<0.01)。TESS评定显示不良反应发生率低,程度轻。结论:文拉法辛联合米氮平治疗难治性抑郁症安全有效更多还原

【Abstract】 Objective:To explore the curative effect and safety of the treatment by using the combination of venlanfaxine and mirtazapine for refractory depression. Method:31 cases of patient with refractory depression by the combination of mirtazapine and venlanfaxine for 8 weeks.Hamilton depression rating scale(HAMD) and treatment emergent symptoms scale(TESS) were used to assess the curative effect and adverse reactions of the treatment respectively. Results:HAMD score changed from(23.32±5.25) at pretreatment to(19.03±4.27) (t=3.53,P<0.01) at week 2;to(8.77±5.18) (t=9.83,P<0.01) at week 8.TESS evaluation showed a low incidence of adverse reactions. Conclusion:Venlanfaxine and mirtazapine is safe and effective in the treatment patients with refractory depression.更多还原